FIELD: medicine.
SUBSTANCE: treating cerebral oedema is the patients with chronic liver diseases is ensured by administering an ozonised solution of 6-methyl-2-ethyl-3-hydroxypyridine succinate in the ozone concentration of 1.5-7 mg/l.
EFFECT: method enables providing higher clinical effectiveness by activating aerobic paths of glucose oxidation, increasing ATP synthesis, improving tissue microcirculation, stimulating mechanisms of antioxidant protection with no side effects.
9 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATMENT OF CEREBROVASCULAR BRAIN DISORDERS (OPTIONS) | 2017 |
|
RU2659674C1 |
| ANTIOXIDANT AND ANTIHYPOXIC AGENT OF 6-METHYL-2-ETHYL-3-HYDROHYPYRIDINE SUCCINATE | 2008 |
|
RU2398583C2 |
| HEPATOPROTECTOR PREPARATION FOR PROPHYLAXIS AND CORRECTION OF TOXIC HEPATIC LESIONS | 2001 |
|
RU2189817C1 |
| USE OF PHARMACEUTICAL COMPOSITION CONTAINING CHOLINE ALFOSCERATE AND 2-ETHYL-6-METHYL-3-HYDROXYPYRIDINE SUCCINATE AS NEUROPROTECTIVE AGENT IN CEREBRAL ISCHEMIA | 2023 |
|
RU2819828C1 |
| APPLICATION OF BETA-HYDROXYBUTYRATE OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR PREPARATION OF MEDICATION WHICH POSSESSES CYTOPROTECTIVE ACTIVITY, INCLUDING NEUROPROTECTIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC, ANTI-HYPOXIC, ANTI-STRESS, ACTOPROTECTIVE AND ADAPTOGENIC ACTIVITY, MEDICATION AND METHOD OF PREVENTION, RELIEF AND TREATMENT BY MEANS OF SAID MEDICATION | 2009 |
|
RU2426535C2 |
| MEDICINAL AGENT FOR PREVENTING AND TREATING CEREBRAL DISEASES AND METHOD OF TREATING CEREBRAL DISEASES | 2015 |
|
RU2692063C2 |
| METHOD FOR TREATING CRANIOCEREBRAL TRAUMA | 2002 |
|
RU2252023C2 |
| NEUROPROTECTIVE AGENT | 2021 |
|
RU2765956C1 |
| METHOD FOR CORRECTING MORPHOLOGICAL CHANGES IN TRAUMATIC BRAIN INJURY | 2021 |
|
RU2758545C1 |
| PHARMACEUTICAL NEUROPROTECTIVE, ANTIOXIDANT, ANTIHYPOXIC, ANTIAPOPTOTIC AND MEMBRANE PROTECTIVE COMPOSITION AND METHOD OF TREATMENT | 2008 |
|
RU2385722C1 |
